Image (A22e9a33 0c4c 4e0c 8eaf 991e66c50753 01)
Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 70710-1411
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 70710-1411). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (A22e9a33 0c4c 4e0c 8eaf 991e66c50753 02)
Image (A22e9a33 0c4c 4e0c 8eaf 991e66c50753 03)
Image (A22e9a33 0c4c 4e0c 8eaf 991e66c50753 04)
Image (A22e9a33 0c4c 4e0c 8eaf 991e66c50753 05)
Image (A22e9a33 0c4c 4e0c 8eaf 991e66c50753 06)
This appears to be a graph showing the number of patients over time and their response to two different treatments, "VCR.CAP" and "RCHOP". The treatments may be related to cancer therapy, as "R-CHOP" is a standard chemotherapy regimen used to treat some lymphomas. However, without additional context, it is not possible to determine the specific conditions or outcomes being measured.*
Image (A22e9a33 0c4c 4e0c 8eaf 991e66c50753 07)
This appears to be a partial result from a clinical trial comparing two treatments, with data on patient survival ("subjects alive"), a hazard ratio, and a chart showing patient outcomes over time for both treatments ("VeR-CAP" and "R-CHOP"). However, without further context or additional information, it is not possible to provide a more specific or useful description.*
Vial Label (A22e9a33 0c4c 4e0c 8eaf 991e66c50753 08)
This is a product description for a medication called Bortezomib for Injection, used for intravenous or subcutaneous use. Each vial contains 3.5 mg of bortezomib and 35 mg of mar. The usual dosage varies and should be found on the accompanying packaging. Storage should be at 25°C, and unused portions should be discarded. There are specific excursions permitted for temperature, as specified. Natural materials were not used in the manufacturing of the container closure. The medication is manufactured by Zys Hospira Oncology Pt Ltd in Anmedehad, I, and distributed by Zycus Phamaceuticals (USA) Inc. in Penringon, NJ. Code No: G DRUBSIGIZA26T.*
Carton (A22e9a33 0c4c 4e0c 8eaf 991e66c50753 09)
This is a medication instruction for Bortezomib, which comes in the form of an injection for intravenous or subcutaneous use. Each vial contains 3.5 mg/vial of reconstituted Bortezomib. The medication should be stored between 15°C to 30°C and should be protected from light. The manufacturer is Zydus Pharmaceuticals and the medication is only available with a prescription. Details on reconstitution can be found on page 2 of the package insert.*
Carton (inside Flap) (A22e9a33 0c4c 4e0c 8eaf 991e66c50753 10)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
